Is it time for a cardiovascular primary prevention trial in the elderly?
OBJECTIVE
Statins have been shown conclusively to reduce the risk of cardiovascular events in subjects with clinical cardiovascular disease or diabetes aged 65 to 80 years of age. However, few data are available for primary prevention of cardiovascular disease in those aged > or =70 years.


RESULTS
A moderate-dose statin was of little benefit in a population aged 70 to 82 years when given for 3 years in the setting of suboptimally treated blood pressure. More evidence supports the use of blood pressure-lowering medications, but few data are available regarding the appropriate blood pressure target and most effective agents in the elderly. Some evidence also suggests that the elderly could experience higher mortality with antihypertensive treatment. These findings, along with greater safety concerns and an increasing number of competing risks and medical conditions with advancing age, make it imperative to carefully evaluate the risk/benefit balance from treating hypercholesterolemia and hypertension in persons aged > or =70 years.


CONCLUSIONS
We propose a 5-year 2x2 factorial trial of primary prevention in the elderly that will (1) evaluate whether statin therapy will reduce the risk of cardiovascular events when added to the treatment of hypertension to achieve a blood pressure <140/90 mm Hg in most patients and (2) determine the most appropriate blood pressure regimen for the prevention of cardiovascular and renal events.
Robinson
Jennifer G
JG
Lipid Research Clinic, Department of Epidemiology, University of Iowa, Iowa City, IA 52242, USA. jennifer-g-robinson@uiowa.edu
Bakris
George
G
Torner
James
J
Stone
Neil J
NJ
Wallace
Robert
R
D000368:Aged; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011322:Primary Prevention / Q000379:methods* / Q000639:trends; D013997:Time Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors